Professor Cheng-Hock Toh, from the Department of Clinical Infection, Microbiology and Immunology, delivered a plenary speech at the Hong Kong International Biotechnology Conference and Exhibition (BIOHK) last week.
BIOHK brought together biotech leaders, innovators, and stakeholders to explore emerging technologies and shape the future of global healthcare, attracting over 10,000 delegates from 20 countries.
Professor Toh commented: “It was an honour to speak at this world-class biotechnology convention, especially when three leading nations in drug discovery, China, Korea and Taiwan, are in the region.”
Professor Cheng-Hock Toh is a clinical academic with an interest in Haemostasis and Thrombosis. In 2022 he was conferred a Commander of the British Empire (CBE) in 2022 for services to Haematology and Medicine. He has held various national roles including President of the British Society for Haematology, Academic Vice President of the Royal College of Physicians (RCP), and Chair of the National Blood Transfusion Committee.
His presentation on the future of in vitro diagnostics was titled ‘From bench to bedside: aligning diagnostic innovation with real world clinical needs’. It drew on translational research and highlighted the University of Liverpool spin-out company, Sepsis Ltd, alongside his investment experience with Frequasense Ltd - the first company backed by Lyva Labs, the Liverpool City Region’s Innovation Fund.
Professor Toh also spoke about his experience of impactful policy work from his time as Academic Vice President of the RCP, where he championed the integration of research into clinical care contributing to the Health and Care Act 2022.